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Clinical evidence of warm autoimmune hemolytic anemia is 
present in 1 percent to 10 percent of patients whose direct 
antiglobulin test (DAT) is negative. The clinical underpinnings 
associated with DAT-negative immune hemolysis are poorly 
understood, and the current study aimed to further define the 
clinical characteristics associated with this form of anemia. 
A 19-question survey, requesting clinical information about 
each patient, was retrospectively mailed to all referring labs 
that had sent patient samples for an enhanced DAT evaluation 
from January 2011 through June 2013. An enhanced DAT 
evaluation involved a standard DAT and DATs performed using 
gel, polyethylene glycol, and 4°C low-ionic strength saline wash. 
We obtained detailed clinical information from 57 patients with 
an enhanced DAT investigation. Eighteen of these 57 patients 
(31.6%) were found to have a positive DAT, 11 (19.3%) of which 
were found to have a positive enhanced DAT (2 were positive 
by enhanced methods and negative by standard methods). The 
reported mean nadir hemoglobin for all 57 patients was 7.8 g/dL 
(range 3.2–12.7), and lactate dehydrogenase was 827.8 U/L (range 
136–6917). Thirty-seven (88.1%) presented with a haptoglobin 
<10 mg/dL, and 21 (48.8%) reported spherocytes on peripheral 
smear. About half of the respondents reported using steroids as 
treatment for the anemia, and 4 of the 18 DAT-positive respondents 
(23.5%) changed their treatment plan because of the reference 
laboratory results. One patient died as a result of the reported 
hemolytic anemia (2.0%). We conclude that immune hemolysis 
detected by enhanced DAT methods is relatively common, and 
enhanced DAT methods are valuable tools in the diagnosis and 
management of patients with DAT-negative hemolytic anemia. 
Immunohematology 2015;31:108–115.
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The detection of red blood cell (RBC)-bound IgG and/or 
complement by a direct antiglobulin test (DAT) remains the 
main assay in the diagnosis of warm autoimmune hemolytic 
anemia (WAIHA).1 A positive DAT almost always exists in 
association with WAIHA and forms the basis for the serologic 
diagnosis.2–4 Several methodologies have been used in the 
detection of these globulins, but the most common and gold 
standard method is the conventional tube method.5 A negative 
DAT, however, does not exclude the diagnosis of WAIHA,4 and 
1 percent to 10 percent of patients with clinical WAIHA have 
been reported to have a negative DAT with no detectible serum 
antibodies.6–9
There have been three hypotheses explaining WAIHA 
associated with a negative DAT. First, as the standard DAT 
can only detect about 150 to 200 molecules of IgG per RBC,9 
these patients may carry a lower number of IgG molecules 
per RBC than the detection threshold for the test, yielding a 
false-negative tube DAT.10 Second, these patients may have 
a low-affinity IgG that dissociates from RBCs during the 
saline washes performed in the standard DAT procedure.2,11 
Lastly, these patients may have clinically significant non-IgG 
immunoglobulins, such as IgA, that are not detected by the 
standard DAT.2,11
Whether or not the clinical entity of DAT-negative 
WAIHA differs significantly from DAT-positive WAIHA in 
terms of underlying pathogenic mechanisms, the severity 
of presentation, treatments, and clinical outcomes has been 
rarely studied.12,13 To increase our clinical knowledge of DAT-
negative hemolytic anemias, we report the serologic results 
of patient samples that were submitted to our diagnostic 
reference laboratory for a DAT-negative WAIHA evaluation. 
We then correlated these reference laboratory results with the 
results of a 19-question survey that defined additional clinical 
and laboratory characteristics for these patients.  
Materials and Methods
Serologic Detection
We retrospectively evaluated the results of all samples that 
were received from January 2011 through June 2013 for an 
enhanced DAT evaluation. The enhanced DAT evaluation at 
the BloodCenter of Wisconsin immunohematology reference 
laboratory involves a standard tube DAT, a gel, 4°C low-
ionic-strength saline (LISS) wash, and a polyethylene glycol 
(PEG) DAT for all samples. All of these methods, including 
the standard DAT, are run in parallel. Standard DAT methods 
are well documented, and our lab used a polyspecific (rabbit 
and mouse) antihuman globulin (AHG) (Ortho, Raritan, 
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NJ), monospecific (monoclonal, mouse) anti-IgG (Immucor, 
Norcross, GA), anti-C3b, -C3d (Immucor), anti-C3d (Ortho 
Clinical Diagnostics, Raritan, NJ), and a 10% albumin control 
(Millipore, Kankakee, IL). The technique will not be further 
described here. For the enhanced methods, the gel test DAT 
was performed as described by the manufacturer (ID-Micro-
Typing System, Ortho Clinical Diagnostics) using the MTS 
Anti-IgG card™ (rabbit). The 4°C LISS Wash (ELU-KIT 
II, Immucor) DAT used cold polyspecific AHG (rabbit and 
mouse antihuman globulin, Ortho Clinical Diagnostics), cold 
monoclonal anti-IgG (Immucor), and a cold 10% albumin 
control (Millipore). The 4°C LISS wash technique was 
performed by washing the sample RBCs four times with ice-
cold (4°C) LISS using a refrigerated centrifuge. The RBCs 
were resuspended to a 2–5% suspension in LISS; one drop 
was added to two drops of cold anti-IgG or cold 10% albumin, 
centrifuged, and read immediately. The 10% albumin served 
as a control for the presence of a cold autoagglutinin; a positive 
result with the 10% albumin control invalidated the 4°C LISS 
wash test. The 20% PEG (Fisher Scientific, Fairlawn, NJ) 
technique (prepared in-house) was performed similarly to 
techniques described elsewhere.14  
Patient Information 
An institutional review board–approved 19-question 
survey was mailed to all referring labs that sent patient 
samples for an enhanced DAT evaluation from January 2011 
through June 2013. Surveys were mailed 1 to 12 months 
after an enhanced DAT sample was received. The survey 
requested additional clinical information about each patient, 
including nadir hemoglobin, bilirubin, lactate dehydrogenase 
(LDH), haptoglobin, current diagnosis, treatment modality, 
and patient outcome. The questions included a combination 
of multiple choice and free response answers. The survey 
questions and answer choices are available in Figure 1. 
Statistical Analysis 
Patient and enhanced DAT data were summarized as 
means, standard deviations, and percents, as applicable. A 
comparison between those with and without a DAT-positive 
test result was performed. Frequency data were analyzed 
using a Fisher’s exact test, and continuous data were analyzed 
using an independent-sample t test. A p ≤ 0.05 was considered 
statistically significant.  
Results
Serologic Findings
We received and performed an enhanced DAT on 447 
samples from January 2011 until June 2013. The samples 
came from 213 female patients (47.7%) and 234 (52.3%) male 
patients. The average reported patient age for these reference 
lab samples was 51.1 years (±22.2 years) and ranged from 1 
year to 99 years of age.  
The summary of serological data is presented in Table 1. Of 
the 447 samples submitted for an enhanced DAT evaluation, 
103 (23.0%) were positive for at least one standard DAT 
method, and of these, 28 (27.2%) were found to be positive for 
only complement. We further identified that 107 (23.9%) of 
the 447 samples were positive for at least one of the enhanced 
methods. Only 37 (34.6%, 8.3% overall) of the 107 samples 
were positive with an enhanced method but negative with the 
standard polyspecific DAT method, and only 8 (7.5%) samples 
were positive with an enhanced method when positive for 
only complement using standard methods. Five (13.5%) of the 
37 were positive for a combination of enhanced methods, 18 
(48.6%) were positive only with gel, 14 (37.8%) were positive 
only with 4°C LISS, and none were positive with PEG alone 
(two samples were positive by PEG and gel).
Clinical Findings
 Of the 447 surveys mailed, we received additional clinical 
information regarding 57 DAT-negative patients (response 
rate: 12.6%). There were more female than male patients (37 
female, 64.9%) in this cohort, and the average reported age 
DAT-negative hemolytic anemia
Table 1. Summary of the battery of serologic tests used for a DAT-
negative autoimmune hemolytic anemia evaluation
Results (N=447) Number positive (%)
Any positive standard polyclonal AHG 103 (23.0)
Any positive standard C3 or IgG 85 (19.0)
Any positive enhanced test 107 (23.9)
• Standard DAT negative 37 (8.3)
Any positive for multiple enhanced methods 50 (11.2)
• Standard DAT negative 5 (1.1)
Any gel test positive 39 (8.7)
• Standard DAT negative 18 (4.0)
Any 4°C LISS test positive 17 (3.8)
• Standard DAT negative 14 (3.1)
Any PEG test positive 1 (0.2)
• Standard DAT negative 0
DAT = direct antiglobulin test; AHG = antihuman globulin; LISS = low-ionic-
strength saline; PEG = polyethylene glycol.
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was 48 (±25.2) years with a range of 1 to 90 years. Of the 57 
patients, 39 (68.4%) were negative by all testing methods. Of 
those who tested positive, 16 (28.1%) had a positive standard 
polyspecific DAT, with 4 (7.0%) being positive for the standard 
polyspecific DAT alone, 6 (10.5%) being positive for IgG alone, 
3 (5.3%) being positive for C3 alone, and 3 (5.3%) having both 
IgG and C3 coating their RBCs. Eleven of the 18 patients with 
a positive DAT (61.1%) had at least one positive enhanced DAT 
(4 [22.2%] 4°C LISS positive, 6 [33.3%] PEG positive, and 11 
[61.1%] gel positive). Only 2 (18.2%) of the 11 respondents 
had a positive enhanced DAT (both gel only) with a negative 
standard polyspecific DAT in our laboratory (Table 2).
1. Prior to sending the enhanced DAT sample, what were the lab 
values for the patient in question:
a. Nadir hemoglobin: 
b. LDH: 
c. Reticulocyte Count: 
d. Total Bilirubin: 
e. Haptoglobin: 
2. Prior to sending the enhanced DAT sample, was a peripheral 
smear evaluated for the patient in question:
a.  Yes
b.  No
3. If a peripheral smear was evaluated, were spherocytes present?
a.  Yes
b.  No
4. What was the patient’s working diagnosis prior to sending the 
enhanced DAT sample?
a. Warm autoimmune hemolytic anemia
b. Cold agglutinin disease
c. Paroxysmal cold hemoglobinuria
d. Delayed hemolytic transfusion reaction
e. Acute hemolytic transfusion reaction
f. Drug induced hemolytic anemia
g. Other (If other, please describe): 




6. If yes, which disease process was present (please choose any 
that apply)?
a. Lymphoma




f. Other (If other, please describe): 
7. Were any therapeutic treatments used for the hemolytic anemia?
a.  Yes
b.  No






f. Other (If other, please describe): 
9. Were the noted treatments started before or after the enhanced 
DAT sample was sent?
a.  Before
b.  After
10. Were any other send out tests done to rule out/in alternative 




11. If yes, what other tests were sent?
12. Did the results of the enhanced DAT change your diagnosis?
a.  Yes
b.  No




14. If your treatment plan changed, what specifically changed?
15. Was the enhanced DAT valuable in managing this patient?
a.  Yes
b.  No
16. What is your current diagnosis for this patient?
17. What is the current status of this patient?
a.  Deceased
b.  Active disease (stable under treatment)
c.  Active disease (unstable under treatment)
d.  Disease resolved




19. If the patient’s hemolytic anemia resolved, how long did it take to 
resolve?
Fig. 1. The 19-question survey mailed to each of the ordering labs.
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Antibody specificities were further classified by the refer-
ence lab when possible (Table 2). Of the 18 total respondents 
who had a positive DAT (enhanced and/or standard), serum or 
eluate evidence of warm autoantibodies was noted in 9 (50%) 
of these patients, followed by 5 (27.8%) cold autoantibodies, 
3 (16.7%) “low affinity” warm autoantibodies (suggested 
by a positive enhanced LISS DAT, and negative standard 
monoclonal IgG DAT), and 1 (5.6%) alloantibody (anti-E). 
Two of the 18 patients were also found to have evidence of a 
drug-induced hemolytic anemia (cefotetan and carboplatin) 
as the cause of their DAT-negative evaluations. The two 
patients who had a negative standard polyspecific DAT, but 
a positive enhanced DAT, were both suggested to have warm 
autoantibodies (one was also found to have an anti-I in the 
serum).  
A summary of selected survey questions for the 57 
patients is presented in Table 3. Overall, patients presented 
with anemia (hemoglobin mean 7.8 g/dL ± 2.1, range 3.2–
12.7 g/dL), hyperbilirubinemia (mean 4.1 mg/dL ± 4.32), 
and evidence of hemolysis, as demonstrated by an elevation 
in LDH, low haptoglobin, and the presence of spherocytes. A 
majority of respondents reported that the patient did not have 
a known disease process associated with a hemolytic anemia 
(32 respondents, 56.1%), and of those who did, hematologic 
malignancy (lymphoma, chronic lymphocytic leukemia, 
chronic myelocytic leukemia, B-cell or T-cell acute lymphocytic 
leukemia, multiple myeloma, hemophagocytic syndrome) 
was the most commonly reported diagnosis (15 respondents, 
26.3%). Other reported associated diagnoses included colon/
lung/ovarian cancer, sickle cell disease, artificial heart valves, 
and hypothyroidism. About half of the patients were treated 
with steroids for their anemia, and most started this therapy 
prior to the enhanced DAT evaluation (64.3%). After the 
DAT evaluation was reported, 85.7 percent (42 respondents) 
reported not changing their selected therapies, and 77.6 percent 
(38 respondents) did not alter their reported diagnosis. The 
most common reported diagnosis after DAT was hematologic 
malignancy (12 patients, 25.5%), followed by WAIHA (8 
patients, 17.5%), immune hemolysis (5 patients, 10.5%), or 
sepsis (5 patients, 10.5%). Less frequently reported diagnoses 
included solid organ malignancy, microangiopathic hemolysis, 
mechanical hemolysis, congenital red cell defects, prematurity, 
Table 2. Serologic results of the survey respondents who had a positive DAT*
Standard DAT Enhanced DAT
Patient # Poly IgG C3
4C LISS 
(IgG) PEG Gel Serum Eluate Antibody Type
1 0 0 0 0 0 + 0 + Warm auto
2 0 0 0 0 0 + Anti-I 0 Warm auto, cold auto
3 + 0 + 0 0 0 0 0 NA
4 + 0 + 0 0 0 Anti-I 0 Cold auto
5 + 0 + 0 0 0 Anti-I 0 Cold auto
6 + 0 0 0 0 0 Antibody with broad specificity + Warm auto
7 + 0 0 0 0 0 0 0 NA
8 + 0 0 + 0 + Antibody with broad specificity 0 Low affinity warm auto
9 + 0 0 + + + Antibody with broad specificity 0 Low affinity warm auto
10 + + 0 0 0 0 0 + Warm auto
11 + + 0 0 + + 0 0 NA
12 + + 0 0 + + Antibody with broad specificity 0 Warm auto
13 + + 0 + + + 0 + Warm auto, low affinity warm auto 
component
14 + + 0 + 0 + Antibody with broad specificity + Warm auto
15 + + + 0 + + Anti-E, Anti-I 0 Allo, cold auto, warm auto
16 + + + 0 0 + 0 0 Drug ab (cefotetan)
17 + + 0 0 0 0 0 0 Drug ab (carboplatin)
18 + + + 0 + + Antibody with broad specificity, 
anti-I
+ Warm auto, cold auto
*0 = negative; + = positive, any strength.
DAT = direct antiglobulin test; Poly = polyclonal; LISS = low-ionic-strength saline; PEG = polyethylene glycol; NA = not available; auto = autoantibody; allo = 
alloantibody; ab = antibody.
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coronary artery disease, occult bleeding, and vasculitis.  Most 
patients recovered or became stable with treatment (64.7%), 
and while 14 patients were reported as deceased, only 1 death 
was reported as caused by the hemolytic process (1.8%). The 
average recovery time was 2.7 months, with a reported range 
of 1 week to 1 year.
We statistically compared the survey responses of those 
18 patients who were found to have a positive reference lab 
DAT (any method) from those who did not. While the numbers 
were small, we found no significant difference in patient gender 
distribution or age (Table 3). While we found that those with 
a positive DAT had a lower mean nadir hemoglobin, higher 
mean LDH, and higher mean bilirubin than those who had 
a negative DAT, none of these differences reached statistical 
significance (p > 0.05). Moreover, the frequency of reported 
associated diagnoses, treatments used, and patient outcome did 
not differ based on the DAT result.  In contrast, we did find that 
there was a significant difference in physician responses to the 
results. Specifically, we found that 7 of 17 (41.2%) respondents 
changed their patient’s working diagnosis when the DAT was 
reported to be positive, whereas only 4 of 32 (12.5%) reported 
a change in diagnosis after a negative DAT result (p = 0.03). 
We also found a trend where more respondents (DAT positive: 
4 of 17, 23.5%, DAT negative: 3 of 32, 9.4%, p = 0.2) changed 
M.S. Karafin et al.
Table 3. Summary of selected survey responses from the labs requesting an enhanced evaluation for a reported DAT-negative hemolytic 
anemia (N=57)
Survey Question Overall responses (N=57)
Respondents with a negative 
DAT (N=39)
Respondents with a positive 
DAT (N=18) p value
Demographics







Patient age — avg (± sd) 48.0 (± 25.2) 47.8 (± 27.5) 48.4 (± 20.1) 0.93
Lab Values — avg (± sd)
Nadir hemoglobin (g/dL) 7.8 (± 2.1) 8.2 (± 2.3) 7.0 (± 1.5) 0.051
LDH (U/L) 827.8 (± 1164.6) 778.6 (± 856.7) 947.1 (± 1737.4) 0.65
Total bilirubin (mg/dL) 4.1 (± 4.3) 3.5 (± 4.2) 4.96 (± 4.5) 0.27
Haptoglobin (# reported below the lower limit of detection) 37/42 (88.1%) 21/28 (75.0%) 10/14 (71.4%) 1.0
Spherocytes present on smear 21/43 (48.8%) 14/28 (50.0%) 7/15 (46.7%) 1.0
Associated Diseases
Lymphoma 5/23 (21.7%) 4/15 (26.7%) 1/8 (12.5%) 0.62
Lupus 0 0 0 NA
Mycoplasma 0 0 0 NA
Mononucleosis 1/23 (4.3%) 1/15 (6.7%) 0 1.0
Viral syndrome 0 0 0 NA
Other (i.e., ALL, CLL) 18/23 (78.3%) 11/15 (73.3%) 7/8 (87.5%) 0.62
Treatments
Steroids 25/50 (50%) 13/28 (46.4%) 12/22 (54.5%) 0.8
Rituximab 3/50 (6%) 1/28 (3.6%) 2/22 (9.1%) 0.6
Splenectomy 1/50 (2%) 1/28 (3.6%) 0 1.0
IVIG 3/50 (6%) 0 3/22 (13.6%) 0.1
Plasma exchange 2/50 (4%) 0 2/22 (9.1%) 0.2
Outcome
Death 14/51 (27.5%) 7/35 (20.0%) 7/16 (43.8%) 0.1
Active disease (stable) 16/51 (31.4%) 12/35 (34.3%) 4/16 (25.0%) 0.5
Active disease (unstable) 4/51 (7.8%) 3/35 (8.6%) 1/16 (6.3%) 1.0
Disease resolved 17/51 (33.3%) 13/35 (37.1%) 4/16 (25.0%) 0.5
DAT = direct antiglobulin test; LDH = lactate dehydrogenase; ALL =  acute lymphocytic leukemia; CLL = chronic lymphocytic leukemia; IVIG =  intravenous 
immunoglobulin; sd = standard deviation.
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treatment plans when the DAT was reported to be positive. Of 
those who changed their treatment plan because of a positive 
DAT result, 50 percent (2/4) specifically added steroids as a 
treatment, and 1 discontinued steroid therapy (patient with 
the drug-induced hemolytic anemia). Only one of the three 
respondents (33%) who changed a treatment plan because of 
the negative DAT result specifically reported discontinuing 
steroid use.
Discussion
The current study aimed to provide a clinical-pathologic 
correlation for patients with suspected immune DAT-negative 
hemolytic anemia, regardless of the cause. Of the 447 samples 
evaluated during the study interval, we found that about 1 
in 4 DAT-negative referrals were positive with enhanced 
methods. This finding was complicated by the fact that most 
of these positive studies were also positive with standard 
DAT methods in our reference lab and that only 8.3 percent 
of samples were positive using DAT-enhanced methods alone. 
Our survey revealed that the clinical characteristics of patients 
with a DAT-positive and DAT-negative evaluation did not 
differ significantly, though knowledge of a positive enhanced 
DAT result caused significantly greater changes to the patient’s 
reported diagnosis, and altered treatment plans.
The phenomenon of clinically evident WAIHA with a 
negative DAT has been known for decades.4,15 Worlledge and 
Blajchman (1972)16 reported that 3 percent of 333 patients 
with AIHA were DAT negative; Chaplin reported a similar 
incidence8; Petz and Garratty studied 347 patients with 
suspected AIHA and found an incidence of 7 percent (11% if 
including all referred samples);17 and Boccardi et al. reported 
that 11 percent of their patients with WAIHA were DAT 
negative.15 Our data, finding 8.3 percent of cases to be DAT 
negative using standard methods, are consistent with these 
previous studies. 
As the methods used for detecting warm autoantibodies 
have improved, many reference labs are now using a 
combination of enhanced methods, such as those performed 
by our reference laboratory, to detect low-level antibodies, low-
affinity antibodies, and non-IgG antibodies.2,9,13 Our serologic 
findings are similar to those published previously using 
standard methods. First, studies, such as that performed 
by Leger et al.9 and Garratty et al.,18 found that many cases 
submitted for a suspected DAT-negative hemolytic anemia 
(10–50%) had a positive standard DAT result when handled 
by their reference laboratory. These differences are significant, 
because they demonstrate and confirm that differences in 
technique and methodology can dramatically influence the 
quality of hospital laboratory DAT results.9 In our laboratory, 
we also found that 23 percent of samples submitted for a 
DAT-negative hemolytic anemia had a positive standard DAT, 
supporting these previous observations.  Second, we found 
a similar proportion of positive DAT results using enhanced 
methods.  In the study performed by Leger et al.,9 4.9 percent of 
samples were positive by LISS alone, 2.0 percent by polybrene 
alone, and 0 percent by gel alone. When excluding those that 
were positive by standard DAT methods, we also found that 
3.1 percent of samples were positive only with 4°C LISS, none 
were positive with PEG alone, and 4.0 percent were positive 
only with gel.  
To our knowledge, our study is the first in the U.S. to 
evaluate clinical information on a cohort of 57 patients with a 
suspected DAT-negative hemolytic anemia and then correlate 
these findings with reference laboratory serologic results. The 
findings from our survey are consistent with, and expand upon, 
the observations from other previous studies.13 Specifically, 
DAT-negative WAIHA has been associated with non-
Hodgkin’s lymphomas,19,20 certain chemotherapeutic drugs 
(such as fludarabine, cyclophosphamide, and rituximab),21 
certain hematopoietic stem cell transplants,22 autoimmune 
diseases such as Sjogren syndrome,23 kidney transplants,24 
certain solid organ malignancies,25 and pregnancy.26 Similarly, 
our 18 DAT-positive respondents reported that their hemolytic 
anemia was associated with acute leukemia status post–bone 
marrow transplant, myelodysplastic syndrome, and sickle cell 
disease.
We also confirmed that steroids are the most common 
treatment for our patient cohort and that these treatments 
generally resulted in disease remission or stability. This 
observation is consistent with what has been previously 
reported. Case studies reveal that patients with DAT-negative 
hemolytic anemia are generally responsive to steroids,13,19,27,28 
but recurrences of the hemolytic anemia20,23 and treatment 
failures (one requiring splenectomy) have been reported.27 
To our knowledge, the largest study to investigate the clinical 
characteristics and outcomes for DAT-negative hemolytic 
anemia was performed by Kamesaki et al.13 In their 
retrospective review, they identified 154 patients over a 7-year 
period with DAT-negative hemolytic anemia. They found that 
91 percent responded to steroids, 70 percent entered remission 
in 4 weeks, and 84 percent survived at least 1 year. While fewer 
of our cohort reported that they used steroids (about 50%), 
we still found that when steroids were used, more than half 
demonstrated remission or stability of disease. The differences 
between our study, and that done by Kamesaki et al. are likely 
DAT-negative hemolytic anemia
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attributable to the differences in the lab methods used to detect 
DAT-negative hemolytic anemia and the differences in how we 
categorized DAT-positive from DAT-negative patient cohorts. 
Our study has some notable limitations. First, despite our 
best efforts, our survey response rate was quite low.  Identified 
reasons for this low response rate included unexpected 
changes to physician address that could not be further 
clarified, and large numbers of corporate referring labs that 
did not have access to patient data. The limited response rate 
added a possible selection bias that cannot be fully accounted 
for. However, we feel that our data are generally representative, 
since our findings are similar to other published literature 
on this topic. Second, most of our respondents had DATs 
that were positive by both the enhanced and the standard 
methods. Consequently, the subsequent patient data reviewed 
does not represent the clinical characteristics of truly DAT-
negative hemolytic anemia. What we can say, however, is that 
the data reviewed here likely represent the characteristics 
of those patients who had a negative DAT at some point 
in their diagnostic workup and were suspected to have a 
DAT-negative hemolytic anemia. Lastly, while we evaluated 
hundreds of DAT-negative samples, we could only provide 
clinical correlations for a small number of cases. Because of 
sample size and the varying test methods used, we were not 
able to determine the cause for the negative DAT in these 
patients (i.e., low number of IgG molecules or significant 
non-IgG immunoglobulins). IgA-induced hemolytic anemia, 
specifically, was not represented in our cohort, and only two 
cases of low-affinity antibodies (LISS positive, monoclonal 
IgG negative) were evaluated in our survey sample.  
In conclusion, this study suggests that using a battery of 
enhanced methods to evaluate cases of possible DAT-negative 
autoimmune hemolytic anemia is valuable, and changes to 
diagnosis and treatment plans were identified when a DAT-
positive result was obtained from a formerly DAT-negative 
patient. Moreover, the use of enhanced techniques in the 103 
cases with positive standard DATs increased the confidence 
that immunoglobulin was truly binding to red cells. Clearly, 
no single test can be used to predict the presence of significant 
autoantibodies, and our study supports an increasing body 
of literature that DAT-negative and DAT-positive hemolytic 
anemias appear similar in etiology, treatment, and general 
outcome. Additional larger prospective studies are needed to 
further elucidate the qualities that make patients with DAT 
negative hemolytic anemia unique.
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